E7386 Study 102: Global Dose-Expansion Cohort of E7386 + Lenvatinib (Len) in Patients (Pts) with Advanced Endometrial Cancer (Aec) That Progressed on Platinum-Based Chemotherapy (Chemo) and an Anti-Pd-(L)1 Immunotherapy (Io).
AuthID
P-01A-3WT
P-01A-3WT